10.7.2017 17:48 | Business Wire
Pharnext to Present PXT864 Data at the Alzheimer's Association International Conference 2017
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that data related to PXT864, the Company’s lead PLEODRUG™, in development for the treatment of Alzheimer’s disease (AD), will be presented in two posters at the Alzheimer's Association International Conference 2017 (AAIC), July 16-20, in London, England.
Details are as follow:
PXT864 is a novel synergistic combination of baclofen and acamprosate given as a pill twice-daily. PXT864 acts through a new mechanism of action that targets metabolic imbalance in the brain of patients suffering from neurodegenerative diseases. PXT864’s most advanced indication is Alzheimer’s disease. Development in other neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), is also planned.
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in
Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Media Relations (Europe)
+33 (0)1 44 54 36 64
René Goedkoop, +33 (0)1 41 09 22 30
Chief Medical Officer
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
Media Relations (U.S.)
Financial Communication (France)
Emmanuel Huyn, +33 (0)1 44 71 20 40
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
MITSUI-CHEMICALS26.7.2017 04:02 | pressemeddelelse
Mitsui Chemicals Starts Accepting Applications on September 1st for 2018 Mitsui Chemicals Catalysis Science Award
CA-NOMINUM25.7.2017 21:54 | pressemeddelelse
Nominum-led Panel Discussion at BlackHat Focuses on the Agility and Coverage Depth of DNS in Discovering and Blocking New Malware
OR-USB-IMPLEMENTERS25.7.2017 18:02 | pressemeddelelse
USB 3.0 Promoter Group Announces USB 3.2 Update
KSA-MOCI25.7.2017 16:11 | pressemeddelelse
King Salman Appoints Commissions to Develop Al-Ola and Diriyah Gate into Major Tourist Attractions
CA-ANDERSEN-TAX25.7.2017 15:32 | pressemeddelelse
Andersen Global Announces Collaboration with UnityFour and Pistiolis-Triantafyllos & Associates in Greece and Cyprus
JANSSEN25.7.2017 15:31 | pressemeddelelse
Janssen Announces Phase 3 Pivotal Study Results for Darunavir-Based Complete Treatment Regimen
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum